Spending on medical services for people enrolled in employer-sponsored health plans increased 44% between 2007 and 2016, according to researchers from the Health Care Cost Institute (HCCI).

The double whammy of rising healthcare costs and an aging population could cause a ripple of negative impacts across the U.S. economy.

Gilead Sciences Inc. will sell cheaper versions of its blockbuster hepatitis C drugs, the original versions of which sparked widespread debate about U.S. pharmaceutical costs when they were introduced at a price of more than $1,000 a pill.

Drug companies usually get what they want in public-policy battles on Capitol Hill, but a move by the pharmaceutical industry to grab $4 billion from the federal Treasury in a bill that is supposed to address the nation’s deadly opioid epidemic is meeting fierce resistance.

Workplace wellness programs that offer employees a financial carrot for undergoing health screenings, sticking to exercise regimens or improving their cholesterol levels have long been controversial.

A federal court ruled this month that a Montana insurer is entitled to federal compensation for subsidy payments under the Affordable Care Act that President Trump abruptly ended last October, a ruling that could reverberate through insurance markets and cost the government hundreds of millions of dollars.